Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
Idorsia Ltd (IDIA.SW) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 34.61 M | 1.22 B | 1.7 B | 577.99 M | 319.38 M |
| 2022 | 95.45 M | 1.25 B | 1.81 B | 1.05 B | 689.47 M |
| 2021 | 19.3 M | 1.23 B | 1.59 B | 1.71 B | 1.25 B |
| 2020 | 12.26 M | 574.73 M | 982.45 M | 1.66 B | 1.2 B |
| 2019 | 16.54 M | 425.77 M | 970.86 M | 1.16 B | 896.35 M |